Halia Therapeutics to Present at Asia BIO 2024
*Presentation to be held on Wednesday, April 24, from 2:00 – 2:15 p.m. SGT LEHI, Utah, April 17, 2024 /PRNewswire/ — Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat...
Halia Therapeutics to Present at BIO-Europe Spring 2024 Conference
Presentation to be held on Tuesday, March 19, from 11:30 a.m. – 11:45 a.m. CET LEHI, Utah, March 12, 2024 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule...
Halia Therapeutics to Present at 2024 BIO CEO & Investor Conference
LEHI, Utah, Feb. 21, 2024 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced that David J. Bearss, Ph.D., President and CEO of Halia...
Halia Therapeutics Initiates Phase II Clinical Trial to Evaluate Efficacy of HT-6184, a First-in-Class NEK7/NLRP3 Inhibitor, on Post-Procedural Inflammatory and Pain Responses
The first patient undergoing wisdom tooth extraction has been dosed with HT-6184 to evaluate its effect on post-procedure diagnostic biomarkers of inflammation and pain, as well as to evaluate its safety and tolerability. LEHI, Utah, Feb. 15, 2024 /PRNewswire/...
Halia Therapeutics Announces Collaboration with Canary Speech to Leverage its Cutting Edge AI-Driven Speech Technology to Advance the Clinical Development of Novel Therapeutics Targeting Neuroinflammation
This technology will support the development of Halia's new Alzheimer's disease drug, HT-4253, targeting a mediator of neuroinflammation called Leucine-rich repeat kinase 2 (LRRK2) LEHI, Utah, Feb. 6,...
Halia Therapeutics Announces $30M Series C Financing to Advance Novel Pipeline of Anti-Inflammatory Therapeutics
Series C Financing will support the advancement of lead programs in Phase II clinical trials, evaluating HT-6184, Halia’s first-in-class NLRP3/NEK7 inflammasome inhibitor, and advancing additional programs into the clinic. LEHI, Utah, January 31,...
Halia Therapeutics to Attend the 42nd JP Morgan Healthcare Conference and Present at Biotech Showcase in San Francisco
LEHI, Utah, Jan. 4, 2024 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company, is pioneering a novel class of small molecule medications designed to combat inflammation. Today, the company announced that its leadership team will attend the...
Halia Therapeutics to Present at the 13th World Gastroenterology, IBD & Hepatology Conference
LEHI, Utah, Dec. 15, 2023 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced that the company will present at the 13th...
Halia Therapeutics Dosed its First Patient in Phase 2a Clinical Trial of HT-6184, a First-in-Class NLRP3-Inhibitor, for the Treatment of Lower-Risk Myelodysplastic Syndromes
LEHI, Utah, Dec. 13, 2023 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced the dosing of the first patient in Phase 2a clinical trial...
Halia Therapeutics to test HT-6184 in MDS patients for first time
The Phase II trial of HT-6184 will enroll around 50 patients with MDS who are or are on the borderline of being transfusion-dependent. Halia Therapeutics is looking to start a Phase II trial of its pipeline candidate HT-6184 in myelodysplastic syndrome (MDS) early...
Halia Therapeutics Announces Positive Phase 1 Clinical Trial Results for HT-6184 at the 5th Inflammasome Therapeutics Summit
LEHI, Utah, Nov. 29, 2023 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to combat inflammation, today announced positive results following the successful...
Halia Therapeutics to Present New Preclinical Data at the 65th American Society of Hematology (ASH) Annual Meeting & Exposition
Halia will present 3 posters with new positive data and a company showcase providing an overview of its clinical programs targeting the inflammasome LEHI, Utah, Nov. 27, 2023 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company...
Halia Therapeutics to Present at the 5th Inflammasome Therapeutics Summit
LEHI, Utah, Nov. 20, 2023 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced that David...
Halia Therapeutics Appoints Former Amgen Director of Global Regulatory Affairs, Lisa Shamon, Ph.D., as Vice President of Regulatory Affairs and Former Amgen Scientist, Xianne Leong Penny, Ph.D., as Senior Medical Director
SALT LAKE CITY, Nov. 16, 2023 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced the...
Halia Therapeutics Continued Support to Utah’s Industry Community Recognized by First Place at the Utah Business Innovation Awards
Halia Therapeutics has been awarded first place in the Medical & Health: MedTech category of the Utah Business Innovation Awards
Halia Therapeutics to Present at the 17th Annual Pain Therapeutics Summit
LEHI, Utah, Oct. 18, 2023 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced that Jared Bearss, MBA,...
Halia Therapeutics to Present at the 17th Annual PAINWeek Conference
Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced they will be presenting new data at the 17th Annual PAINWeek Conference on Thursday, September 7, at 5:30 p.m. PDT/8:30 p.m. EDT.
Halia plans two trials testing its anti-inflammatory lead candidate
The company plans to start two Phase II trials later this year, with a further Phase I trial planned for early 2024.
Halia Therapeutics Opens the Doors of its New Headquarters and Laboratory Facilities in Lehi, Utah
SALT LAKE CITY, Aug. 16, 2023 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced the opening of its new...
Halia Therapeutics Announces Completion of Enrollment for Phase I Clinical Trial of HT-6184
- Halia expects to release data from the Phase I trial in Q4 2023 SALT LAKE CITY, Aug. 7, 2023 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases that are driven by chronic...
Contact Us
Corporate Headquarters
3900 N. Traverse Mountain Blvd., Suite 100
Lehi, Utah 84043
United States
info@haliatx.com | +1 (385) 355-4315